RenaSci

Glucose Tolerance Tests

Glucose Tolerance Tests

 

Glucose tolerance tests can be used to assess the antidiabetic potential of novel drugs.  Plasma samples are taken before and after drug administration and at multiple time points post-glucose to evaluate the effects of the novel agent on the plasma glucose and insulin excursions produced by the glucose load. Animals may be fasted overnight to reduce variability and to enable stable baseline glucose and insulin levels to be measured before the glucose tolerance test.

 
Key features of the glucose tolerance tests offered by RenaSci are :-


     •     Rats or mice
     •     Normal lean animals or rodent models of insulin resistance and type 2 diabetes
           (dietary and STZ)
     •     Genetically-predisposed animals eg ob/ob mice, db/db mice and Zucker 
           diabetic fatty fa/fa (ZDF) rats
     •     Acute, sub-chronic or chronic drug treatment
     •     Compounds and glucose dosed po, ip or iv
     •     Standard glucose and insulin determinations (10 μl plasma)
     •     Multiple blood-sampling (up to 8 from cannulated rats)
     •     Other analysis and sampling for PK on request.
     •     Simultaneous measurement of urinary glucose excretion if required


All glucose tolerance tests are customised to meet the specific requirements of each client and include advice on experimental design, statistical analysis by a qualified statistician, fully audited data pack and written reports to regulatory standards if required.

 

GLP-1: Acute IVGTT in Lean Mice

 

Tolbutamide and Vildagliptin: Acute OGTT in Lean Rats

 

Effect of Metformin on Glucose Tolerance in ob/ob Mice

 

Insulin tolerance tests (ITT) are also available in mice or rats. Please contact us for further information.  

 

Posters


Cheetham et al. 2008.  Effect of the MCH1 antagonist, GW803430, on body weight, food and water intake, glucose tolerance, fat pad weight, ex vivo binding and various plasma parameters in dietary-induced obese C57BL/6J mice. Program No. 584.24. Society for Neuroscience Meeting, Washington, DC, 15th-19th November 2008.

 

Surman et al. 2011. ALB-127158(a): An MCH1 receptor antagonist that exhibits weight loss and improvements in insulin sensitivity in diet-induced obese mice. Abstract No. 0108-LB. American Diabetes Association 71st Scientific Sessions, San Diego, California, 24th-28th June 2011.

 

Vickers et al. 2011. Effect of STZ dose and dosing regimen on the diabetes phenotype of C57BL/6J mice fed a high fat diet. Diabetes Summit, Philadelphia, Pennsylvania, 7th-8th March 2011.

 

Vickers et al. 2012. Effect of empagliflozin on body weight, glucose control and plasma parameters in STZ-induced diabetic rats fed a high-fat diet: comparison with exenatide. Poster No. 771. European Association for the Study of Diabetes (EASD), Berlin, Germany, 1st-5th October 2012.

 

Manuscripts

 

Jones et al. 2014. Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats. Eur J Pharmacol 729: 59-66. [PubMed]

 

Moser et al. 2014.  Antidiabetic effects of the Cimicifuga racemosa extract Ze 450 in vitro and in vivo in ob/ob mice. Phytomedicine  21: 1382-1389. [PubMed]

 

Vickers et al. 2014. Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body weight reduction and glucose homeostasis of obese rats fed a cafeteria diet. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 7: 265-275. [PubMed]